Sale!

HAINS Mycobacterium Tuberculosis Second Line Drug Resistance Profile Test Cost

Original price was: 1,170 د.إ.Current price is: 1,050 د.إ.

-10%

The HAINS Mycobacterium Tuberculosis Second Line Drug Resistance Profile Test is a sophisticated diagnostic procedure designed to identify resistance against second-line anti-tuberculosis drugs. This test is crucial for tailoring treatment plans for tuberculosis (TB) patients, especially those with multidrug-resistant TB (MDR-TB) or extensively drug-resistant TB (XDR-TB), ensuring they receive the most effective medications. By detecting genetic mutations associated with drug resistance, the test provides rapid, accurate insights into the resistance profile of the Mycobacterium tuberculosis strain affecting the patient.

Performed at DNA Labs UAE, a leading facility in genetic and molecular diagnostics, the test ensures high-quality results, leveraging advanced technology to contribute significantly to the management and control of tuberculosis. The cost of the test is set at 1050 AED, reflecting the intricate technology and expertise involved in conducting this specialized diagnostic procedure. By identifying the resistance pattern, healthcare providers can make informed decisions about the treatment regimen, optimizing patient outcomes and combating the spread of resistant TB strains.

Description

HAINS MYCOBACTERIUM TUBERCULOSIS SECOND LINE DRUG RESISTANCE PROFILE Test

Test Cost: AED 1050.0

Symptoms and Diagnosis

If you suspect Mycobacterium tuberculosis infection and want to determine the drug resistance profile, the HAINS MYCOBACTERIUM TUBERCULOSIS SECOND LINE DRUG RESISTANCE PROFILE Test is a recommended option. This test helps in identifying the presence of drug-resistant strains of M. tuberculosis, allowing healthcare providers to tailor the treatment regimen accordingly.

Test Details

The HAINS (Hybridization in Aminoacyl-tRNA Synthetase) assay is a molecular diagnostic test used to determine the drug resistance profile of Mycobacterium tuberculosis (M. tuberculosis) to second-line drugs. This test specifically targets mutations in the genes associated with resistance to second-line drugs, such as fluoroquinolones (e.g., moxifloxacin, levofloxacin), aminoglycosides (e.g., amikacin, kanamycin), and injectable drugs (e.g., capreomycin).

The HAINS assay involves the extraction of DNA from M. tuberculosis isolates, followed by amplification of specific target regions using polymerase chain reaction (PCR). The amplified DNA is then hybridized with specific probes that are complementary to wild-type and mutant sequences associated with drug resistance. The hybridized DNA is detected using a colorimetric or fluorescence-based method.

The HAINS assay provides information on the presence or absence of specific mutations associated with drug resistance. This allows healthcare providers to tailor the treatment regimen for M. tuberculosis infections based on the individual’s drug resistance profile. It helps in selecting the most effective combination of antibiotics to achieve successful treatment outcomes and prevent the further spread of drug-resistant strains.

Test Components and Price

The HAINS MYCOBACTERIUM TUBERCULOSIS SECOND LINE DRUG RESISTANCE PROFILE Test costs AED 1050.0.

Sample Condition

Submit 3 mL (2 mL min.) of sputum, bronchoalveolar lavages, bronchial aspirates, or cultured growth on appropriate media in a sterile screw capped container. Place the container in a sealed plastic bag and ship refrigerated. DO NOT FREEZE.

Report Delivery

If the sample is received by 11 am, the report will be delivered on Friday.

Method

The HAINS MYCOBACTERIUM TUBERCULOSIS SECOND LINE DRUG RESISTANCE PROFILE Test is conducted using the PCR (Polymerase Chain Reaction) and Line Probe Assay methods.

Test Type

The HAINS MYCOBACTERIUM TUBERCULOSIS SECOND LINE DRUG RESISTANCE PROFILE Test is specifically designed to detect tuberculosis.

Doctor

This test can be ordered by a physician.

Test Department

This test is conducted by the Molecular Diagnostics department at DNA Labs UAE.

Pre Test Information

No special preparation is required before taking this test.

Test Name	HAINS MYCOBACTERIUM TUBERCULOSIS SECOND LINE DRUG RESISTANCE PROFILE Test
Components
Price	1050.0 AED
Sample Condition	Submit 3 mL (2 mL min.) Sputum\/ bronchoalveolar lavages \/ bronchial aspirates \/ Cultured growth on appropriate media in a sterile screw capped container in a sealed plastic bag. Ship refrigerated. DO NOT FREEZE.
Report Delivery	Sample Sat by 11 am, Report Fri
Method	PCR, Line probe assay
Test type	Tuberculosis
Doctor	Physician
Test Department:	MOLECULAR DIAGNOSTICS
Pre Test Information	No special preparation required
Test Details	The HAINS (Hybridization in Aminoacyl-tRNA Synthetase) assay is a molecular diagnostic test used to determine the drug resistance profile of Mycobacterium tuberculosis (M. tuberculosis) to second-line drugs. This test specifically targets mutations in the genes associated with resistance to second-line drugs, such as fluoroquinolones (e.g., moxifloxacin, levofloxacin), aminoglycosides (e.g., amikacin, kanamycin), and injectable drugs (e.g., capreomycin). The HAINS assay involves the extraction of DNA from M. tuberculosis isolates, followed by amplification of specific target regions using polymerase chain reaction (PCR). The amplified DNA is then hybridized with specific probes that are complementary to wild-type and mutant sequences associated with drug resistance. The hybridized DNA is detected using a colorimetric or fluorescence-based method. The HAINS assay provides information on the presence or absence of specific mutations associated with drug resistance. This allows healthcare providers to tailor the treatment regimen for M. tuberculosis infections based on the individual’s drug resistance profile. It helps in selecting the most effective combination of antibiotics to achieve successful treatment outcomes and prevent the further spread of drug-resistant strains.

Browse

Want to chat?

Social